Healthcare / BiotechnologyShanghai
$20.18
-0.93 (-4.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $2.4M · quality 43.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
35.4x
↑EV/EBITDA
14.9x
↑ROE
8.9%
↑Gross Margin
63.4%
↑Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
0.2%
FCF / Net income
0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.53B · net income $155.6M · FCF $2.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.53B | $1.53B | $1.41B | $1.26B | $1.32B |
| Net Income | $155.6M | $155.6M | $31.5M | $-190.3M | $-90.3M |
| EBITDA | $316.6M | $316.6M | $201.3M | $-132.7M | $-41.7M |
| EPS | 0.79 | 0.79 | 0.16 | -0.96 | -0.45 |
| Gross Margin | 63.4% | 63.4% | 68.7% | 70.8% | 75.4% |
| Operating Margin | 6.4% | 6.4% | 9.2% | -18.5% | -9.1% |
| Net Margin | 10.1% | 10.1% | 2.2% | -15.1% | -6.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.80 | 0.80 | 0.75 | 0.69 | 0.57 |
| Current Ratio | 1.50 | 1.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.4M | $2.4M | $12.7M | $-278.3M | $-485.1M |
| Returns | |||||
| ROE | 8.9% | 8.9% | 1.9% | -11.7% | -5.0% |
| Valuation | |||||
| P/E | 35.40 | 35.40 | 129.62 | — | — |
| EV/EBITDA | 14.91 | 14.91 | 23.58 | — | — |
| P/B | 2.27 | 2.27 | 2.50 | 2.70 | 2.47 |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | 11.7% | -4.3% | — |
| EPS Growth | 393.8% | 393.8% | 116.7% | -113.3% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.4%
EPS terminal req.
$1.79
Spread vs growth
362.4%
5Y implied EPS CAGR
22.4%
EPS terminal req.
$2.17
Spread vs growth
371.4%
10Y implied EPS CAGR
16.0%
EPS terminal req.
$3.49
Spread vs growth
377.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.4%
Start / end P/E
261.3x → 25.5x
EPS bridge
0.16 → 0.79
Residual
-355.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.